Clinical Impact of Hybrid Capture–Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer

Journal of Thoracic Oncology

Volumn 12, Issue 2, 2017, Pages 258-268

  Rozenblum, Anna Belilovski ^a,b   Ilouze, Maya ^a   Dudnik, Elizabeth ^a   Dvir, Addie ^c   Soussan Gutman, Lior ^c   Geva, Smadar ^a   Peled, Nir ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c TEVA PHARMACEUTICALS   (Israel)

Author keywords

Driver mutations; Immunotherapy; Next generation sequencing; Oncogenic drivers; Precision personalized medicine; Targeted therapy

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; BEVACIZUMAB; CABOZANTINIB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PEMETREXED; PERTUZUMAB; SCATTER FACTOR RECEPTOR; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; VINORELBINE TARTRATE; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; AGED; ALK GENE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; EGFR GENE; ERBB2 GENE; FEMALE; GENE MUTATION; HUMAN; HYBRID CAPTURE BASED NEXT GENERATION SEQUENCING; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MET GENE; NEXT GENERATION SEQUENCING; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ADENOCARCINOMA; CANCER STAGING; CLINICAL DECISION SUPPORT SYSTEM; DNA SEQUENCE; FOLLOW UP; GENE REARRANGEMENT; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG TUMOR; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; PROCEDURES; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; DECISION SUPPORT SYSTEMS, CLINICAL; FEMALE; FOLLOW-UP STUDIES; GENE REARRANGEMENT; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 85015291158     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.10.021     Document Type: Article

References (36)

1. 1 Cooper, W.A., Lam, D.C., O'Toole, S.A., et al. Molecular biology of lung cancer. J Thorac Dis 5:suppl 5 (2013), S479–S490.
2. 2 Schiller, J.H., Harrington, D., Belani, C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002), 92–98.
3. 3 Weinstein, I.B., Cancer. Addiction to oncogenes—the Achilles heel of cancer. Science 297 (2002), 63–64.
4. 4 Califano, R., Abidin, A., Tariq, N.U., et al. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non-small cell lung cancer. Cancer Treat Rev 41 (2015), 401–411.
5. 5 Shlomi D OA, Gottfried, M., et al. Better selection model for EML4-ALK fusion gene test in patients with non-small-cell lung cancer. J Cancer Ther 4 (2013), 54–58.
6. 6 Bar, J., Cyjon, A., Flex, D., et al. EGFR mutation testing practice in advanced non-small cell lung cancer. Lung 192 (2014), 759–763.
7. 7 Pekar-Zlotin, M., Hirsch, F.R., Soussan-Gutman, L., et al. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist 20 (2015), 316–322.
8. 8 Peled, N., Rozenblum, A.B., [Lung cancer treatment in 2015: advances and future outlook]. Harefuah 154 (2015), 510–511 540 [in Hebrew].
9. 9 Tan, D.S., Yom, S.S., Tsao, M.S., et al. The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: status in 2016. J Thorac Oncol 11 (2016), 946–963.
10. 10 Kris, M.G., Johnson, B.E., Berry, L.D., et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311 (2014), 1998–2006.
11. 11 Chia, P.L., Mitchell, P., Dobrovic, A., et al. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol 6 (2014), 423–432.
12. 12 Lopez-Chavez, A., Thomas, A., Rajan, A., et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol 33 (2015), 1000–1007.
13. 13 Korpanty, G.J., Graham, D.M., Vincent, M.D., et al. Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front Oncol, 4, 2014, 204.
14. 14 Kwak, E.L., Bang, Y.J., Camidge, D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363 (2010), 1693–1703.
15. 15 Paez, J.G., Jänne, P.A., Lee, J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004), 1497–1500.
16. 16 Naidoo, J., Drilon, A., Molecular Diagnostic testing in non-small cell lung cancer. Am J Hematol Oncol 10 (2014), 4–11.
17. 17 Thomas, F., Desmedt, C., Aftimos, P., et al. Impact of tumor sequencing on the use of anticancer drugs. Curr Opin Oncol 26 (2014), 347–356.
18. 18 Frampton, G.M., Fichtenholtz, A., Otto, G.A., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31 (2013), 1023–1031.
19. 19 Stroun, M., Anker, P., Lyautey, J., et al. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 23 (1987), 707–712.
20. 20 Lanman, R.B., Mortimer, S.A., Zill, O.A., et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS One, 10, 2015, e0140712.
21. 21 Schwarzenbach, H., Hoon, D.S., Pantel, K., Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11 (2011), 426–437.
22. 22 Jones, S., Anagnostou, V., Lytle, K., et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med, 7, 2015 283ra53.
23. 23 National Comprehensive Cancer Network. NCCN guidelines for non–small cell lung cancer. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed May 1, 2016.
24. 24 Rizvi, N.A., Hellmann, M.D., Snyder, A., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
25. 25 Gagan, J., Van Allen, E.M., Next-generation sequencing to guide cancer therapy. Genome Med, 7, 2015, 80.
26. 26 Heuckmann, J.M., Thomas, R.K., A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine. Ann Oncol 26 (2015), 1830–1837.
27. 27 Takeda, M., Sakai, K., Terashima, M., et al. Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer. Ann Oncol 26 (2015), 2477–2482.
28. 28 Konig, K., Peifer, M., Fassunke, J., et al. Implementation of amplicon parallel sequencing leads to improvement of diagnosis and therapy of lung cancer patients. J Thorac Oncol 10 (2015), 1049–1057.
29. 29 Deeb, K.K., Hohman, C.M., Risch, N.F., et al. Routine clinical mutation profiling of non-small cell lung cancer using next-generation sequencing. Arch Pathol Lab Med 139 (2015), 913–921.
30. 30 Pfarr, N., Stenzinger, A., Penzel, R., et al. High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer. Genes Chromosomes Cancer 55 (2015), 30–44.
31. 31 Drilon, A., Wang, L., Arcila, M.E., et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res 21 (2015), 3631–3639.
32. 32 Paweletz, C.P., Sacher, A., Raymond, C.K., et al. Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clin Cancer Res 22 (2016), 915–922.
33. 33 Peled, N., Palmer, G., Hirsch, F.R., et al. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol 7 (2012), e14–e16.
34. 34 Lindeman, N.I., Cagle, P.T., Beasley, M.B., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 8 (2013), 823–859.
35. 35 Middleton, G., Crack, L.R., Popat, S., et al. The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer. Ann Oncol 26 (2015), 2464–2469.
36. 36 Abrams, J., Conley, B., Mooney, M., et al. National Cancer Institute's precision medicine initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Educ Book, 2014, 71–76.